Johnson & Johnson Sharpens its Pipeline Profile with Billion-Dollar Acquisition and Study Successes!
Reading Time: 3 minutes
Ophthalmology Deal: J&J acquires Ollin Biosciences for up to $3.33 billion, Blackstone finances the Phase 3 study with $750 million Psychiatry & Oncology: Second positive Phase 3 study for Caplyta in bipolar mania with a 73% response rate in prostate cancer Venture Capital: J&J participates in a $100 million round for Delix Therapeutics to explore non-hallucinogenic psychedelics The US pharmaceutical company Johnson & Johnson (i)(JNJ) is advancing the expansion of its drug pipeline with a series of clinical and financial adjustments....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.

